Table 3.

Model-adjusted risk of mortality complemented by restricted mean survival time analysis according to type of anti–COVID-19 therapy in patients with cancer and SARS-CoV-2 infection

Cox proportional modelCovariates
TherapyHR (95% CI)Sex (M/F)Age (<65/≥65 years)Tumor stage (advanced/nonadvanced)RMST difference (95% CI)
P valueP value
Antimalarials only (n = 182)0.41 (0.26–0.66)1.20 (0.89–1.63)2.81 (1.90–4.17)1.20 (0.87–1.66)8.00 (5.50–10.52)
 vs. no drug (n = 446)P < 0.0001P = 0.23P < 0.0001P = 0.27P < 0.0001
Antivirals only (n = 16)0.75 (0.32–1.79)1.35 (1.00–1.89)2.96 (1.90–4.62)1.13 (0.78–1.63)0.29 (−0.19–0.77)
 vs. no drug (n = 446)P = 0.52P = 0.08P < 0.0001P = 0.51P = 0.23
Tocilizumab (n = 51)0.80 (0.37–1.74)1.43 (1.03–2.00)2.61 (1.74–3.92)1.28 (0.90–1.82)2.64 (0.90–4.38)
 vs. no drug (n = 446)P = 0.57P = 0.03P < 0.0001P = 0.16P = 0.003